Radius Health Inc. (NASDAQ:RDUS) shares traded up 2.4% on Tuesday . The stock traded as high as $53.98 and last traded at $53.63, with a volume of 414,344 shares traded. The stock had previously closed at $52.37.

Several research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a report on Monday. Jefferies Group reaffirmed a “hold” rating on shares of Radius Health in a report on Friday. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $70.00 price target on shares of Radius Health in a report on Friday. Maxim Group cut shares of Radius Health from a “hold” rating to a “sell” rating and set a $24.00 price target on the stock. in a report on Thursday, August 4th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Radius Health in a report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $63.66.

The stock’s 50 day moving average is $42.47 and its 200-day moving average is $35.76. The firm’s market capitalization is $2.31 billion.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.06. During the same period last year, the firm posted ($0.61) EPS. Equities research analysts anticipate that Radius Health Inc. will post ($3.72) EPS for the current year.

Other hedge funds and institutional investors have modified their holdings of the company. Dimensional Fund Advisors LP acquired a new position in shares of Radius Health during the fourth quarter valued at $1,362,000. Wells Fargo & Company MN boosted its position in shares of Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock valued at $25,984,000 after buying an additional 29,601 shares in the last quarter. Mutual of America Capital Management LLC boosted its position in shares of Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock valued at $2,245,000 after buying an additional 5,683 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock valued at $4,249,000 after buying an additional 18,259 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Radius Health by 1.7% in the fourth quarter. Swiss National Bank now owns 36,100 shares of the biopharmaceutical company’s stock valued at $2,222,000 after buying an additional 600 shares in the last quarter.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.